C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.
Company profile
Ticker
CCCC
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
C4T Securities Corporation ...
IRS number
475617627
CCCC stock data
Analyst ratings and price targets
Current price
Average target
$12.00
Low target
$9.00
High target
$15.00
Wells Fargo
Maintains
$9.00
JP Morgan
Downgraded
$15.00
Latest filings (excl ownership)
8-K
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
9 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
3 Nov 22
8-K/A
Submission of Matters to a Vote of Security Holders
22 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
4 Aug 22
8-K
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
2 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 22
DEFA14A
Additional proxy soliciting materials
17 Jun 22
8-K
Departure of Directors or Certain Officers
17 Jun 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 52.83 mm | 52.83 mm | 52.83 mm | 52.83 mm | 52.83 mm | 52.83 mm |
| Cash burn (monthly) | 2.58 mm | 9.27 mm | 10.83 mm | 8.93 mm | 9.34 mm | 8.54 mm |
| Cash used (since last report) | 10.56 mm | 37.92 mm | 44.31 mm | 36.54 mm | 38.22 mm | 34.95 mm |
| Cash remaining | 42.27 mm | 14.91 mm | 8.52 mm | 16.29 mm | 14.61 mm | 17.88 mm |
| Runway (months of cash) | 16.4 | 1.6 | 0.8 | 1.8 | 1.6 | 2.1 |
Institutional ownership, Q3 2022
76.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 109 |
| Opened positions | 15 |
| Closed positions | 20 |
| Increased positions | 45 |
| Reduced positions | 32 |
| 13F shares | Current |
|---|---|
| Total value | 327.63 mm |
| Total shares | 37.36 mm |
| Total puts | 0.00 |
| Total calls | 28.10 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Wasatch Advisors | 5.93 mm | $52.05 mm |
| ArrowMark Colorado | 5.09 mm | $44.66 mm |
| BLK Blackrock | 3.46 mm | $30.38 mm |
| T. Rowe Price | 2.96 mm | $26.00 mm |
| RTW Investments | 2.82 mm | $24.73 mm |
| Vanguard | 2.02 mm | $17.71 mm |
| Bain Capital Life Sciences Investors | 1.64 mm | $14.40 mm |
| Soleus Capital Management | 1.44 mm | $12.64 mm |
| Pictet Asset Management | 1.31 mm | $11.45 mm |
| JHG Janus Henderson | 818.75 k | $7.18 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 Jan 23 | Kenneth Carl Anderson | Common Stock | Option exercise | Acquire M | No | No | 4.98 | 444 | 2.21 k | 95,128 |
| 6 Jan 23 | Kenneth Carl Anderson | Common Stock | Option exercise | Acquire M | No | No | 2.11 | 268 | 565.48 | 94,684 |
| 6 Jan 23 | Kenneth Carl Anderson | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.98 | 444 | 2.21 k | 890 |
| 6 Jan 23 | Kenneth Carl Anderson | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.11 | 268 | 565.48 | 1,067 |
| 3 Jan 23 | Grogan Donna Roy | Common Stock | Grant | Acquire A | No | No | 6.38 | 1,763 | 11.25 k | 2,582 |
| 3 Jan 23 | Kenneth Carl Anderson | Common Stock | Grant | Acquire A | No | No | 6.38 | 1,568 | 10.00 k | 94,416 |
| 3 Jan 23 | Glenn Dubin | Common Stock | Grant | Acquire A | No | No | 6.38 | 1,725 | 11.01 k | 5,235 |
| 3 Oct 22 | Glenn Dubin | Common Stock | Grant | Acquire A | No | No | 8.69 | 1,265 | 10.99 k | 3,510 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
25 Jan 23
Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Lowers Price Target to $9
3 Jan 23
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
19 Dec 22
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
25 Nov 22
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
25 Nov 22
Press releases
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
30 Jan 23
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
9 Jan 23